3bym: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
[[Image:3bym.png|left|200px]] | [[Image:3bym.png|left|200px]] | ||
{{STRUCTURE_3bym| PDB=3bym | SCENE= }} | {{STRUCTURE_3bym| PDB=3bym | SCENE= }} | ||
===X-ray co-crystal structure aminobenzimidazole triazine 1 bound to Lck=== | ===X-ray co-crystal structure aminobenzimidazole triazine 1 bound to Lck=== | ||
{{ABSTRACT_PUBMED_18278858}} | {{ABSTRACT_PUBMED_18278858}} | ||
== | ==About this Structure== | ||
[[3bym]] is a 1 chain structure of [[Proto-oncogene tyrosine-protein kinase]] and [[Tyrosine kinase]] with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3BYM OCA]. | |||
== | ==See Also== | ||
*[[Proto-oncogene tyrosine-protein kinase|Proto-oncogene tyrosine-protein kinase]] | |||
*[[Tyrosine kinase|Tyrosine kinase]] | |||
==Reference== | ==Reference== | ||
<ref group="xtra">PMID: | <ref group="xtra">PMID:018278858</ref><references group="xtra"/> | ||
[[Category: Homo sapiens]] | [[Category: Homo sapiens]] | ||
[[Category: Non-specific protein-tyrosine kinase]] | [[Category: Non-specific protein-tyrosine kinase]] | ||
[[Category: Huang, X.]] | [[Category: Huang, X.]] | ||
[[Category: Atp-binding]] | [[Category: Atp-binding]] | ||
[[Category: Disease mutation]] | [[Category: Disease mutation]] | ||
[[Category: Host-virus interaction]] | [[Category: Host-virus interaction]] | ||
| Line 49: | Line 35: | ||
[[Category: Transferase]] | [[Category: Transferase]] | ||
[[Category: Tyrosine-protein kinase]] | [[Category: Tyrosine-protein kinase]] | ||
Revision as of 10:23, 26 July 2012
X-ray co-crystal structure aminobenzimidazole triazine 1 bound to Lck
Template:ABSTRACT PUBMED 18278858
About this Structure
3bym is a 1 chain structure of Proto-oncogene tyrosine-protein kinase and Tyrosine kinase with sequence from Homo sapiens. Full crystallographic information is available from OCA.
See Also
Reference
- Martin MW, Newcomb J, Nunes JJ, Boucher C, Chai L, Epstein LF, Faust T, Flores S, Gallant P, Gore A, Gu Y, Hsieh F, Huang X, Kim JL, Middleton S, Morgenstern K, Oliveira-dos-Santos A, Patel VF, Powers D, Rose P, Tudor Y, Turci SM, Welcher AA, Zack D, Zhao H, Zhu L, Zhu X, Ghiron C, Ermann M, Johnston D, Saluste CG. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity. J Med Chem. 2008 Mar 27;51(6):1637-48. Epub 2008 Feb 16. PMID:18278858 doi:10.1021/jm701095m
